Skip to main content

Cornell University

Psychedelics are compounds that produce an atypical state of consciousness characterized by altered perception, cognition, and mood. Psychedelics are emerging as promising treatments for a range of neuropsychiatric disorders including depression, substance use disorder, and post-traumatic stress disorder. For example, psilocybin-assisted psychotherapy has been shown efficacious for treating major depression in Phase II trials. A notable feature is the long-lasting benefit: after one or two dosing sessions, reduction of depressive symptoms was durable for weeks and up to several months. Given these exciting early results, psychedelics as medicine have the potential to transform psychiatry. Yet we know very little about how psychedelics modify brain structure and function, fundamental scientific knowledge that can ensure safe and effective use in the clinic.

Cornell is leading the resurgence to understand the basic neurobiology of psychedelics. Collectively, we discovered that a single dose of psilocybin leads to long-lasting rewiring of neuronal connections. We found that LSD and psilocybin can flatten neural dynamics to facilitate switches of recurrent brain states. We have also mapped gene expression changes in the whole brain evoked by psilocybin, and began to explore the actions of rapid-acting psychedelics such as 5-MeO-DMT.

Nerual rewiring demonstrated day 1 through day 34 after adding single dose of psilocybin
A single dose of psilocybin led to long-lasting neuronal rewiring (Shao et al., 2021).
Chemical structures of various types of pasychedelic compounds.
Bridging the gap from chemistry to circuit-level understanding of psychedelic action (Kwan et al., 2022).


Collaborating Faculty Members

Ongoing projects leverage a broad community of researchers at Cornell including Cornell Neurotech and Weill Cornell Medicine. Our goal is to gain a deep understanding for how psychedelics impact brain circuits to exert their remarkable short- and long-term behavioral effects. Researchers include:



  1. Impact of LSD on cerebral blood flow (in partnership with Amanda Feilding and the Beckley Foundation)

    Psychedelics act on serotonin receptors, which are present in blood vessels. The goal of this project is to measure the effects of LSD on cerebral blood flow and neurovascular coupling in mice using high-resolution optical imaging methods. The results will tell us how psychedelics may influence vascular dynamics and blood oxygen level to alter brain activity.

  2. Novel technologies to visualize psilocybin’s plasticity actions

    Our prior work shows that a single dose of psilocybin can lead to enduring increases in neuronal connections in the frontal cortex. This project seeks to extend those findings, by developing a novel optical microscopy method that will enable precise measurement of psilocybin-evoked plasticity over a much greater extent of the brain circuitry and over longer time periods.

  3. Effects of psilocybin on naturalistic social behavior

    A key challenge to studying psychedelics in animal models is the lack of suitable behavioral assays. Cornell researchers have innovated a new paradigm for measuring social behavior in a community of interacting mice. The ecologically realistic approach allows for the mapping of intricate social structure and how group behavioral dynamics are shaped by psychedelics.

  4. Molecular signals responsible for therapeutic effects of ketamine and psilocybin

    Neural rewiring in the brain likely underpins the long-term beneficial effects of psychedelics, however the molecular signals that initiate the plasticity processes remain unidentified. Here, using single-cell sequencing technologies, we are determining the specific molecules in neurons that are essential for kickstarting psychedelics’ effects on neural plasticity.

In the Media

NPR (2022): Brain scientists are tripping out over psychedelics

Cornell Chronicle (2022): Microscopy reveals how psychedelics light up brain’s neuropathways

Weill Cornell Medicine Newsroom (2022): Psychedelic drugs flatten the brain’s dynamic landscape

Nature (2022): Taking the tripping out of psychedelic medicine